Medications

Tesamorelin for Weight Loss: What It Is, How It Works, and What to Expect

Nuvo Health Team · 8 min read

Quick answer

Tesamorelin is a synthetic peptide approved for reducing visceral (belly) fat in HIV patients, but increasingly used off-label for general weight management and body composition. Here's what the evidence says.

If you've been exploring weight loss options beyond GLP-1 medications like Ozempic or Wegovy, you may have come across tesamorelin — a peptide that's been generating significant interest in 2026. Searches for tesamorelin have surged over 400% in recent months, driven by growing curiosity about peptide-based therapies for weight management and body composition.

What Is Tesamorelin?

Tesamorelin (brand name Egrifta) is a synthetic analog of growth hormone-releasing hormone (GHRH). Unlike GLP-1 receptor agonists, which work by mimicking the gut hormone GLP-1 to reduce appetite and slow digestion, tesamorelin stimulates the pituitary gland to produce more growth hormone (GH). Elevated growth hormone, in turn, increases the breakdown of fat — particularly visceral fat stored around internal organs.

How Tesamorelin Works

Tesamorelin binds to GHRH receptors in the pituitary gland, triggering a pulsatile release of growth hormone. This closely mimics the body's natural GH secretion pattern. The downstream effect is an increase in IGF-1 (insulin-like growth factor 1), which promotes fat metabolism — especially the breakdown of visceral adipose tissue (VAT).

Clinical trials in HIV-positive adults showed that tesamorelin reduced visceral fat by approximately 15–18% compared to placebo after 26 weeks. The reduction was largely in the abdominal region, and the effect was sustained as long as the medication was continued.

Tesamorelin vs. GLP-1 Medications: Key Differences

GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) work primarily by suppressing appetite and slowing gastric emptying, leading to significant overall weight loss — often 15–20% of body weight in clinical trials. Tesamorelin takes a fundamentally different approach.

Mechanism: Tesamorelin stimulates GH release; GLP-1 agonists suppress appetite and reduce caloric intake.
Target fat: Tesamorelin preferentially reduces visceral (deep belly) fat; GLP-1s reduce overall body fat and weight.
Muscle: Tesamorelin may preserve or slightly increase lean muscle mass; GLP-1s can cause muscle loss alongside fat loss.
Approval status: GLP-1 drugs are FDA-approved for weight loss; tesamorelin is approved only for HIV-associated lipodystrophy.
Administration: Both require subcutaneous injections (tesamorelin is daily; GLP-1 agonists are once weekly).
Weight loss magnitude: GLP-1 medications produce substantially greater total weight loss for most users.

Who Is Using Tesamorelin Off-Label?

Outside of its approved indication, tesamorelin is used in anti-aging and performance medicine circles for body recomposition — specifically to reduce abdominal fat while preserving or building muscle. It's often discussed alongside other peptides like CJC-1295, Ipamorelin, and BPC-157.

People who are drawn to tesamorelin rather than GLP-1 medications often want to target specifically visceral fat without the significant appetite suppression or GI side effects associated with semaglutide or tirzepatide. Some also use it to help prevent the muscle loss that can accompany GLP-1 therapy.

Side Effects and Risks of Tesamorelin

Like any hormone-modulating therapy, tesamorelin carries risks. Common side effects reported in clinical trials include:

Injection site reactions (redness, pain, itching) — the most common complaint
Fluid retention (edema), particularly in the hands and feet
Joint pain (arthralgia) and muscle pain (myalgia)
Nausea and stomach discomfort
Elevated blood glucose — tesamorelin can worsen insulin resistance
Tingling or numbness (due to fluid shifts around nerves)

Tesamorelin and Insulin Resistance

One clinically significant concern with tesamorelin is its effect on glucose metabolism. By increasing growth hormone, tesamorelin can raise blood sugar levels and reduce insulin sensitivity. In the FDA trials, HbA1c levels were slightly elevated in some patients. This is the opposite of GLP-1 medications like semaglutide, which improve blood sugar control and are widely used in type 2 diabetes. People with prediabetes or diabetes should approach tesamorelin with extra caution.

Does Tesamorelin Work Without a Caloric Deficit?

Research suggests tesamorelin can reduce visceral fat even without a significant change in diet or exercise — which is one reason it's attractive to some users. However, the effect is primarily fat redistribution rather than major weight loss. People tracking the scale may see modest changes; those tracking body composition metrics (waist circumference, DXA scans) may see more meaningful improvements in visceral fat specifically.

Can You Use Tesamorelin Alongside GLP-1 Medications?

Some weight management physicians are exploring combination approaches: using a GLP-1 medication for overall appetite suppression and weight loss, alongside tesamorelin or other GH-releasing peptides to preserve lean muscle and specifically target visceral fat. However, this approach is experimental, not validated in large clinical trials, and carries combined risk profiles. This decision should only be made under close medical supervision.

How Tesamorelin Is Obtained

In the United States, tesamorelin (Egrifta SV) is available by prescription. For off-label use, it's typically prescribed through anti-aging or functional medicine clinics and compounded pharmacies. The cost varies widely — branded Egrifta is expensive (often thousands of dollars per month), while compounded versions may be more affordable but carry their own quality and regulatory considerations.

The Bottom Line

Tesamorelin is a legitimate, FDA-approved peptide with real clinical evidence for reducing visceral fat. Its growing popularity reflects broader interest in peptide therapies and body recomposition, especially among people who want to target belly fat specifically or who are concerned about muscle loss on GLP-1 medications. That said, it is not a substitute for the proven, substantial weight loss delivered by GLP-1 agonists, and its off-label use comes with real risks — including elevated blood glucose.

If you're considering tesamorelin, speak with a physician who can evaluate your individual situation, review your metabolic health markers, and help you understand whether tesamorelin fits your goals — and whether it should be used alone or alongside other therapies.